Our robust protein expression platform consists of all three commonly used protein expression systems: E. coli, yeast, and mammalian cells.
These systems have been thoroughly tested for developing a variety of recombinant proteins, including membrane proteins, cytokines, chemokines, growth factors, hormones, enzymes, and bioengineered antibodies.
Our proprietary technology generates monoclonal antibodies with high specificity and high affinity against native proteins, skips steps for antigen preparation and significantly reduces antibody production time and cost. We have successfully developed many therapeutic monoclonal antibodies that have been validated for diagnosis or therapeutic drugs.
Use of appropriate preclinical models are critical for research studies in addition to drug development.
At PharmaPlanter Technologies, we have developed a comprehensive modelling system to recapitulate human disease conditions. Our proprietary reporter cell lines, conditionally regulated and stable cell models, syngeneic mouse tumor models, PDX (patient derived xenograft) models, and transgenic mouse models are the best tools to study human diseases. Our skilled team members can also provide custom solutions for all preclinical experimental studies to clients from both academic and biotechnological industries.
Phytochemicals are naturally occurring, plant-derived chemicals that determine the color, flavor, and odor of plant products.
Increasingly, more scientific research suggests that consuming foods rich in phytochemicals reduces the risk of chronic diseases and improves overall health and wellbeing. At PharmaPlanter Technologies, we have established a patented technology platform for the extraction and isolation of active phytochemicals from various plants. The platform is equipped with an efficient HPLC (high-performance liquid chromatography) analytical system that can identify and analyze phytocompounds of interest.
In collaboration with scientists at National Chiao Tung University, PharmaPlanter Technologies has developed is equipped with a polymer and chitosan-based formulation technology for the formulation of nanomedicines for site-specific delivery of nanomedicine to their target microenvironments. Additionally, our drug formulation and delivery platforms allow us to develop high-end nutraceutical and cosmeceutical products with improved stability and bioavailability of active biomolecules.
